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Background: In May 2005, a long-distance outbreak of Legionnaires’ disease (LD) caused by Legionella pneumophila
serogroup 1 occurred in south-east Norway. The initial outbreak investigation without serology identified 56
laboratory-confirmed LD cases of whom 10 died. However, 116 patients with community-acquired pneumonia might
belong to the outbreak based on epidemiological investigations, but acute laboratory tests other than serology were
negative or not performed. To assess the true extent of the outbreak, we evaluated two serological assays in order to
reclassify the 116 patients with indeterminate case status.
Methods: Two polyvalent antibody tests, a serogroup 1–6 immunofluorescence assay (IFA) and a serogroup 1–7
enzyme-linked immunosorbent assay (ELISA) were used. They were evaluated with cases defined as culture- or
urinary antigen positive LD patients (n = 40) and non-cases defined as confirmed non-LD patients (n = 39) and
healthy control subjects (n = 62). The 116 patients, who were negative in culture, polymerase chain reaction
and/or urinary antigen tests, were analysed by the same serological assays. Antibodies to the outbreak strain
were determined by immunoblotting.
Results: In the evaluation study, the sensitivity and specificity of a ≥4-fold IFA titre change was 38% and 100%,
respectively, with corresponding values of 30% and 99% for seroconversion in ELISA. A single high positive IFA
titre yielded sensitivity and specificity of 73% and 97%, respectively, with corresponding values of 68% and 96%
for a single high immunoglobulin (Ig) G and/or IgM in ELISA.
Based on this evaluation, the following serological testing identified 47 more LD cases, and the outbreak thus
comprised 103 cases with a case fatality rate of 10%. About the same proportion (70%) of the urinary antigen
positive and negative LD cases had antibodies to the serogroup-specific lipopolysaccharide of the outbreak
strain. In addition to the 103 LD cases, Legionella infection could not be verified or excluded in 32 patients
based on epidemiology and/or lack of microbiological sampling.
Conclusions: The acute-phase tests (culture, polymerase chain reaction, and urinary antigen) identified less than
55% of the 103 patients in this outbreak. Serological testing thus remains an important supplement for diagnosis of
LD and for determination of outbreak cases.
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Legionnaires’ disease (LD) has been considered a rare
cause of community-acquired pneumonia (CAP) in Norway.
The last 10 years, about 6 cases per million inhabitants
were reported annually [1] which is lower than the
incidence rate of more than 10 per million reported in
overall Europe [2]. However, a study in 2005 showed con-
siderable underreporting of the disease in Norway [3].
Insufficient use of diagnostic testing and false negative
diagnostic tests may lead to underreporting in passive
surveillance systems. A disease incidence of almost 80
per million was estimated in a population-based study
[4], and Legionella spp. cause between 2% and 16% of
CAP cases in prospective studies [5-7], rendering Legion-
ella spp. one of the most common pathogens in CAP. L.
pneumophila serogroup 1 (Lp 1) is responsible for 70%
to 90% of all culture positive LD cases [8,9].
Microbiological diagnosis of LD during acute illness is
based on culture, polymerase chain reaction (PCR) of
respiratory samples, and/or detection of Legionella anti-
gen in urine. Isolation of Legionella spp. by culture is
considered the gold standard for diagnosing LD, but
the sensitivity is low. PCR-based methods are rapid
and more sensitive than culture [10], but more experi-
ence in clinical use is needed [11]. The urinary antigen
test (UAT) has become the most performed test in
diagnosing LD [8] because of its easy performance and
rapidity combined with a reasonable sensitivity ranging
from 40% to 94% [12-14]. However, it is only reliable
for Lp 1 infections. Serological tests rarely allow a diag-
nosis during the acute phase and are regarded more
useful for epidemiological purposes.
In May 2005, an outbreak of LD caused by Lp 1 (ST15,
monoclonal subgroup Benidorm [15]) occurred in south-
east Norway [16]. The source was identified as an indus-
trial air scrubber with a long-distance spread of more
than 10 km [16]. In addition, the river Glomma has been
proposed as a disseminator due to the release of waste
water from industrial aeration ponds [17]. The initial out-
break investigation identified 56 patients diagnosed with
LD by a positive Lp 1 culture, PCR, and/or UAT [16], but
serological testing was not performed. As the aim of that
study was mainly to identify the source of the outbreak,
probable cases were not included. In the present inves-
tigation, sera from the laboratory confirmed LD cases
were used to evaluate two commercial serological assays
against L. pneumophila, which previously had been eval-
uated in one study only [18]. Based on the sensitivities
and specificities obtained in our evaluation, the tests were
then employed to measure antibody levels in sera from
all CAP patients, who were referred to the local hospital
during the outbreak. Our aims were to diagnose add-
itional LD cases and so to determine the extent of the
outbreak.Methods
Setting
Østfold Hospital Trust is an acute care hospital that
serves the 260,000 inhabitants of Østfold County, includ-
ing the 120,000 inhabitants of the twin cities Sarpsborg
and Fredrikstad. The regional epidemiology of CAP has
been constant in May/June during the years 2001 – 2004
with an average of 16 referrals per week (2.3 per day) to
the hospital. On 21 May 2005, an LD outbreak was sus-
pected, and the initial outbreak investigation identified
56 cases of LD (53 cases admitted to our hospital and 3
cases to other hospitals in Norway), confirmed by either
a positive Legionella UAT and/or culture of Lp 1 and/or
PCR [16]. In order to identify potentially undiagnosed
cases, adult patients referred to our hospital with ra-
diographically confirmed CAP during a five-week period
from 9 May to 12 June 2005 were invited to a serological
study. The period chosen was based on the previous
report of this outbreak [16]. In addition, healthy controls,
recruited from the hospital staff, were invited in late May
for evaluation of the serological assays. The study was
approved by the Regional Committee for Medical and
Health Research Ethics (REC) South East, P.O BOX
1130, Blindern, NO 0318 Oslo, Norway. Written informed
consent for participation in the study was obtained from
all participants.
Microbiological investigation
Blood cultures were drawn from CAP patients referred
to the emergency department during the five-week
period, and sputum cultures were sampled from patients
with expectoration. Isolated bacterial species were classi-
fied as an aetiological pathogen if predominant growth of
a typical respiratory tract pathogen was observed. Lung
tissue specimens from deceased patients and sputum
were also analysed by a commercial PCR test (Onar Lp-
QP; Minerva Biolabs GmbH, Germany) for detection of
Legionella spp. and cultured for Legionella (plated both
directly and after an acid decontamination step onto
selective and non-selective buffered charcoal-yeast ex-
tract agar). Isolates were serogrouped with Legionella
Latex Test (Oxoid, Basingstoke, UK).
Urine samples from patients and healthy control sub-
jects were analysed by the Now Legionella Urinary Anti-
gen Test and the Now Streptococcus pneumoniae Urinary
Antigen Test (Binax, Portland, Maine) for qualitative de-
tection of soluble Legionella and S. pneumoniae antigen,
respectively.
Sera from CAP patients were collected during the
acute phase (0 – 15 days after symptom onset) if avail-
able, 4 – 6 weeks, and 3 months after hospital admission.
Sera from healthy employees were collected in late May
and after approximately 1 and 3 months. All sera were
stored at −20°C. Two commercial polyvalent serological
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methods and the outbreak investigation: a serogroup 1–6
immunoglobulin (Ig) G/IgM/IgA immunofluorescence
assay (IFA) (Meridian Bioscience Europe, Milan, Italy) and
a serogroup 1–7 enzyme-linked immunosorbent assay
(ELISA) (Serion ELISA classic, Institut Virion/Serion
GmbH, Würzburg, Germany) with separate levels of IgG
and IgM antibodies measured in an ELISA robot (DSX
Automated System, Dynex Technologies, Inc, Virginia).
The coefficients of variation for four standard samples per
plate in this study were 7.6% for IgG (range 4.1 to 10.0)
and 6.6% for IgM (range 5.8 to 7.4) compared with the
maximal interserial coefficient of variation of 16% given
by the manufacturer [19]. Both tests were performed
according to the manufacturers’ instructions and analysed
without knowledge of Lp 1 infection status.
Evaluation of the serological assays
The reference standard for the serological evaluation
was based on the EU case definition [20], but excluding
serology as microbiological evidence of infection. Hence,
patients with radiographically confirmed CAP admitted
during the defined five-week period and with either
isolation of L. pneumophila from a respiratory sample
and/or a positive L. pneumophila UAT were defined as
cases. Patients with confirmed non-LD pneumonia and
healthy control subjects were considered to be non-cases.
The definition of confirmed non-LD pneumonia was
radiographically documented CAP and a negative Legion-
ella UAT and culture with either a) proven aetiology
other than Legionella, b) date of symptom onset before
10 May or after 27 May 2005 (based on the symptom
onset period of the initial 56 cases), and/or c) residency
outside and not visiting the outbreak area which was
defined by the plume model from the aerosol dispersion
investigation [16]. Only LD cases and healthy controls
with paired serum samples were included in the evalu-
ation study.
The assays were evaluated from the antibody responses
corresponding to the EU laboratory criteria for confirmed
and probable cases in addition to an alternative ELISA-
ratio method:
1) Serologically confirmed LD was defined as a ≥ 4-fold
change in IFA titres in paired sera or seroconversion in
ELISA to a positive IgG (≥50 U/ml) or IgM (≥120 U/
ml), which include the borderline ranges given by the
manufacturer [19].
2) Serologically probable LD was defined as a single
high or high standing antibody level with an IFA titre
≥128, as given by the manufacturer, and/or ELISA IgG
≥50 U/ml and/or IgM ≥120 U/ml.
3) An alternative definition of probable LD was based
on a relative change of IgG and/or IgM antibody levels
in paired serum samples in ELISA and calculated for allpaired serum samples including antibody levels below
the manufacturer’s cut-off. To exclude clinically irrele-
vant changes in the low antibody ranges, only sera with
IgG or IgM levels above the 75th percentile of the non-
cases (IgG 16 U/ml and IgM 26 U/ml, respectively),
were considered for this calculation. In paired sera with
antibody levels below these values, the ratio was set to
1.0, indicating no change.
Outbreak investigation
Sera from patients with CAP, who lived within or visited
the outbreak area, but were negative in Legionella culture,
PCR, and/or UAT, were analyzed with the serological
assays. From their antibody responses, patients with posi-
tive serology were defined as confirmed or probable LD
cases and included in the outbreak.
Classification of pneumonia severity
Pneumonia severity was classified by CRB-65 [21], a
score derived by four criteria of severity obtained on
admission: confusion, respiratory rate (>30 per minute),
low blood pressure (diastolic pressure ≤60 mmHg or
systolic pressure ≤90 mmHg), and age ≥65 years. A
CRB-65 score ≥2 was considered to be moderate to
severe pneumonia.
Immunoblotting
To study if the antibody responses, determined in ELISA
and IFA with the polyvalent antigens, were directed to
the serogroup-specific lipopolysaccharide (LPS) antigen
of the Lp 1 outbreak strain [22], immunoblotting with
whole-cell suspensions of this strain was performed as
described previously [23] with detection of IgG and IgM
binding on separate strips. From each patient, the serum
sample (diluted 1:200) with the highest IgG or IgM anti-
body level in ELISA was used. Blotting was also performed
with proteinase K (Qiagen Gmbh, Hilden, Germany)
treated cells [24] from the outbreak strain and from
an Lp 1 isolate of subgroup France/Allentown to study
LPS cross-reactive antibodies. The LPS patterns of the
strains were obtained by silver–staining of sodium do-
decyl sulphate polyacrylamide gels [25] as well as by
incubation of strips with an Lp 1 monoclonal antibody
from the Dresden panel [26]. Antibody binding to the
corresponding LPS region on the strips was recorded
visually as strong, weak, or no response.
Statistical methods
Statistical analyses were performed with SPSS version
16.0. Comparisons between groups were performed using
the χ2 test or independent t-test when appropriate. All
tests were two-sided, and the significance level was set at
0.05. Diagnostic sensitivity and specificity were calculated
for each test using OpenEpi [27]. Correlation between the
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Results
Evaluation of the serological assays
A total of 225 adult patients with CAP of any cause
was referred to our hospital during the defined five-
week period. Before serological testing was performed,
LD and non-LD pneumonia were confirmed in 53 and
56 patients, respectively, leaving 116 patients with un-
known aetiology (Figure 1). Non-LD was confirmed by
the finding of another respiratory pathogen (16 patients),
date of illness onset before 10 May or after 27 May (35
patients), and residency outside and not visiting the
outbreak area (5 patients). The patients included for the
serological assay evaluation comprised 40 LD cases
(median age 68 years, range 35 – 94) and 101 non-casesPatients with CAP referred to the county 
between 9 May and 12 June 2005
(n=225)
Confirmed LD 
(n=40)
CAP patients with 
negative Legionella
culture, PCR and/or 
UAT 
(n=116)
17 non-L
with less
13 LD patients with 
less than 2 sera
LD, positive
serology only 
(n=46)
Non-LD,
sero
(n=
Figure 1 Selection of eligible patients for the serological evaluation s
(grey boxes). Non-LD patients and healthy controls formed the non-cases.
negative Legionella culture, PCR, and/or UAT. Four LD cases (three diagnose
and negative UAT) were admitted to other hospitals in Norway and are no
Legionella urinary antigen test. LD: Legionnaires’ disease (confirmed by Legio(39 non-LD patients, median age 68 years, range 18 – 88,
and 62 healthy controls, median age 45 years, range 24 –
62) from whom two or more sera were collected
(Figure 1).
Sensitivities and specificities of the two serological
assays for the different LD case definitions are shown in
Table 1. The IFA and ELISA results were roughly equal
for both the confirmed and probable LD case definitions,
and combination of both assays resulted in somewhat
better sensitivity without affecting the specificity. The
two serological assays also demonstrated significant cor-
relations between the IFA titres and the sum of IgG and
IgM levels in ELISA with a Spearman rank correlation
coefficient of 0.79 (P < 0.001).
In the alternative ELISA evaluation, the median IgG-
and IgM ratios were 1.7 (interquartile range (IQR) 1.1 –
2.7) and 3.1 (IQR 1.1 – 6.2), respectively, for the LDHealthy controls 
(n=95)
hospital 
 
Confirmed non-LD 
(n=39)
Healthy controls 
(n=62)
D patients 
 than 2 sera
33 controls with 
less than 2 sera
 negative 
logy 
38)
CAP of uncertain 
Legionella status 
(n=32)
tudy. Only individuals with ≥2 paired sera were selected for this study
Also shown are the serological results for the 116 CAP patients with
d with UAT during the acute phase and one with positive serology
t included in the figure. CAP: community-acquired pneumonia. UAT:
nella culture, PCR and/or UAT). Non-LD: CAP of non-Legionella aetiology.
Table 1 Diagnostic sensitivity and specificity of IFA and ELISA tests for different Legionnaires’ disease case definitions
Case definition Serological response Sensitivity (95% CI)
n = 40
Specificity (95% CI)
n = 101
Serologically confirmed LD ≥4-fold titre change in IFA 38 (24 – 53) 100 (96 – 100)
IgM and/or IgG seroconversion in ELISA 30 (18 – 45) 99 (95 – 100)
Combination of IFA and ELISA 53 (38 – 67) 99 (95 – 100)
Serologically probable LD (single high or high
standing antibody level)
IFA-titre ≥128 73 (57 – 84) 97 (92 – 99)
ELISA IgM ≥120 U/ml and/or IgG ≥50 U/ml 68 (52 – 80) 96 (90 – 98)
Combination of IFA and ELISA 78 (63 – 88) 96 (90 – 98)
Serologically probable LD (≥1.5 ratio in ELISA) IgM-ratio ≥1.5 70 (55 – 82) 100 (96 – 100)
IgG-ratio ≥1.5 63 (47 – 76) 98 (93 – 99)
IgM-ratio ≥1.5 and/or IgG-ratio ≥1.5 83 (68 – 91) 98 (93 – 99)
LD: Legionnaires’ disease. Data on sensitivity and specificity are in percent and based on 40 patients with confirmed LD from culture, PCR, and/or UAT and 101
non-cases (39 non-LD pneumonia patients and 62 healthy controls).
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1.14) and 1.09 (IQR 1.00 – 1.24) for the non-cases. The
highest combined sensitivity and specificity were found
for a ratio of >1.5 in paired serum samples for both IgG
and IgM (Table 1).
We found no statistically significant association be-
tween pneumonia severity score and sensitivity of the
serological assays (P > 0.27) for any of the case definitions.Outbreak investigation
During the initial outbreak investigation [16], 116 of the
225 patients referred to our hospital could not beTable 2 Diagnostic tests for Legionnaires’ disease in 103 outb
Case definition Laboratory test No. positi
no. tested
Confirmed LD (direct demonstration
of Lp 1 infection)
Positive Lp 1 UAT* 52/99 (53)
Culture of Lp 1 (sputum)* 4/30 (13)
Culture of Lp 1
(lung tissue)*
6/7 (86)
Positive PCR 8/25 (32)
Confirmed LD** (serology) ≥4-fold titre change
in IFA
40/84 (48)
IgM/IgG seroconversion
in ELISA
30/84 (36)
Probable LD (single high or high
standing antibody level)
IFA-titre ≥128 68/92 (74)
ELISA IgM ≥120 U/ml
and/or IgG ≥50 U/ml
59/92 (64)
Probable LD (ELISA ratio ≥1.5) ELISA IgM ratio ≥1.5
and/or IgG ratio ≥1.5
75/84 (89)
LD: Legionnaires’ disease, Lp 1: L. pneumophila serogroup 1, UAT: urinary antigen te
immunoblots among the serologically confirmed and probable LD cases was simila
*Historical data [16]. Three of these patients were admitted to other hospitals in No
**One of these cases was admitted to another hospital and thus not shown in Figuclassified definitely into LD or non-LD based on Legion-
ella culture, PCR and/or UAT and epidemiological cri-
teria (Figure 1). Following the evaluation study, these
patients were studied by the serological assays using
the three case-definitions as the specificity of more
than 96% (Table 1) in an epidemic setting was consid-
ered acceptable.
Table 2 shows the results of all utilized tests. Fifty-six
cases were previously diagnosed with LD by the acute
phase tests [16], of which UAT was the most important.
PCR and culture of sputum and lung tissue were positive
in eight and ten cases, respectively, but the additive contri-
bution of these tests was limited to four cases. However,reak patients
ve/
(%)
Additional (cumulative)
no. of LD-cases
Comments
52
1 (53) Pos. UAT : 3
Neg UAT: 1
3 (56) Pos UAT: 3
Neg UAT: 2
UAT not done: 1
0 (56) Sputum: 5/22
Lung tissue: 3/3
25 (81) 13 patients had ≥4-fold titre change
in IFA, but no seroconversion in ELISA.
6 (87)
9 (96)
1 (97)
6 (103)
st. The proportion of serogroup 1 specificity to the outbreak strain on
r (70%) to that of the culture, PCR, and/or UAT-confirmed LD cases.
rway and thus not shown in Figure 1.
re 1.
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source [16].
Serologically confirmed or probable LD was found in
47 patients (Table 2). Thirty-one of the cases had con-
firmed LD demonstrated by a ≥4-fold titre change in IFA
or seroconversion in ELISA. One of these, a local resident
from the outbreak area, was admitted to another hospital
and therefore not included in Figure 1. Ten cases had
probable LD shown by a single high or high standing
antibody titres. The alternative use of ELISA IgG/IgM-
ratios, added only six cases to the total number. Thus,
our data indicated that the outbreak comprised at least
103 cases.
LD was ruled out in 38 patients based on negative ser-
ology, whereas Legionella infection could not be verified
or excluded in the remaining 32 CAP patients (Figure 1).
Twelve of these patients refused participation, seven had
cognitive failure, ten died without microbiological sam-
pling, and three had positive serology consistent with
probable LD but died before Legionella exposure could be
clarified, and neither UAT nor autopsy was performed.Table 3 Demographic and serological data among LD patient
Positive culture/PCR/UAT (n =
Age, mean years ± SD 69 ± 14
Male gender 34 (61)
Chronic respiratory disease 11 (20)
Active smoker 22 (39)
Previously healthy 20 (36)
Date of symptom onset 16. May
(interquartile range [IQR]) (14.–19. May)
Inpatient treatment 55 (98)
C-reactive protein (mg/L) ± SD 296 ± 116
ICU-admission 19 (34)
CRB-65 score ≥2 33 (59)
Infiltrate > one lobe 13 (23)
Mortality 10 (18)
IFA-titre, acute phase 64 (0 – 256)
IFA-titre, after 1 month 256 (64 – 1024)
IFA titre, after 3 months 128 (32 – 1024)
ELISA IgG, acute phase 41 (10 – 115)
ELISA IgG, after 1 month 53 (27 – 188)
ELISA IgG, after 3 months 60 (17 – 312)
ELISA IgM, acute phase 24 (4 – 93)
ELISA IgM, after 1 month 47 (22 – 195)
ELISA IgM, after 3 months 21 (10 – 76)
Demographic data are no. (%) of patients unless otherwise indicated. Serological re
IgG and IgM.
ICU: Intensive care unit. CRB-65 score ≥2 indicates moderate to severe pneumonia.The mean age for the 103 LD cases was 67 years
(range 35 – 94), and there were 64 males and 39 fe-
males. Ten of the cases, with a median age of 80 years
(range 69 – 94), died during hospitalisation (case fatality
rate 10%). The demographic and serological results in
Table 3 showed few significant differences between the
two LD patient groups diagnosed by culture, PCR, and/
or UAT and serology, respectively. The latter group had
less severe pneumonia, no deaths, and less frequent
intensive care unit (ICU) admission than LD cases diag-
nosed in the acute phase. No statistically significant
differences in antibody levels were observed between the
two groups except for a higher IgM level at 3 months
among cases with a positive culture/PCR/UAT.
Compared with all 94 non-LD patients (56 patients
with confirmed non-LD and 38 patients with negative
serology, Figure 1), LD cases had more severe pneumonia
(P = 0.048) and a higher proportion of ICU admission
(P = 0.019) than non-LD patients (Table 4). However,
chronic respiratory disease was more frequent in the
non-LD group (P = 0.002). The group of 32 CAP patientss diagnosed by acute phase tests and serology
56) Positive serology only (n = 47) P-value
65 ± 12 0.15
30 (64) 0.75
11 (23) 0.64
17 (36) 0.69
18 (38) 0.79
16. May
(14.–19. May) 0.90
45 (96) 0.45
237 ± 89 0.15
2 (4) <0.001
16 (34) 0.012
9 (19) 0.83
0 (0) 0.002
32 (0 – 64) 0.16
128 (128 – 256) 0.11
64 (32 – 128) 0.15
20 (9 – 52) 0.25
66 (30 – 193) 0.96
33 (12 – 131) 0.20
8 (3 – 150) 0.15
29 (16 – 87) 0.11
11 (6 – 30) 0.04
sults are given in median (interquartile range) titre for IFA and U/ml for ELISA
Table 4 Demography of different patient groups referred to the hospital during the outbreak
Legionnaires’ disease (n = 103) CAP, non-Legionella (n =94) CAP of uncertain Legionella status (n = 32)
Age, mean years ± SD 67 ± 13 65 ± 17 75 ± 16
Male gender 64 (62) 50 (53) 15 (47)
Active smoker 39 (38) 28 (30) 6 (19)
Chronic respiratory disease1 22 (21) 39 (41) 12 (38)
Diabetes 16 (16) 12 (13) 3 (9)
Previously healthy 38 (37) 26 (28) 6 (19)
Inpatient treatment 100 (97) 85 (90) 29 (91)
ICU-admission2 21 (20) 8 (9) 4 (13)
CRB-65 score ≥23 48 (47) 28 (30) 15 (47)
Infiltrate > one lobe 23 (22) 12 (13) 3 (9)
Mortality 10 (10) 6 (6) 6 (19)
1P = 0.002.
2P = 0.019.
3P = 0.048.
Patients with Legionnaires’ disease, community-acquired pneumonia (CAP) of non-LD aetiology and CAP of uncertain Legionella status referred to hospital from
9 May to 12 June are shown. Data are no. (%) of patients unless otherwise indicated. P-values in footnotes indicate the comparison between Legionnaires’ disease
and CAP of non-Legionella aetiology.
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and mortality, but statistical comparisons of this group
with the two others are less reliable due to its hetero-
geneity as described above. Figure 2 demonstrates the
hospitalisation date for patients with LD diagnosed by
culture/PCR/UAT and serology, respectively, non-LD,
and CAP of unknown aetiology during the defined
five-week period. The number of admissions for LD
cases mirrored the outbreak epidemic curve [16]. The
non-LD admission curve, which was expected to fluc-
tuate around a mean of 2.3 per day based on
hospitalization rates in 2001 – 2004, also peaked, but
two days after the outbreak alert. This curve indicated
an over-referral of approximately 15 non-LD patients
probably caused by the media attention following theMay 2005 Date of admission
15
10
5
1
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
N
o.
 o
f 
pa
tie
nt
s
Outbreak alert
Figure 2 Cases of Legionnaires’ disease and community-acquired pneoutbreak. The 32 patients with CAP of unknown aetiology
were scattered throughout the period with a peak two
days before the outbreak alert.
Lp 1 specificity of LD case sera
Immunoblotting was performed to test whether the anti-
body responses observed with the polyvalent ELISA and
IFA were directed to the serogroup-specific LPS of the
Lp 1 outbreak strain. Sera from 44 culture/UAT-positive
and 45 UAT-negative/serology positive LD cases were
available for immunoblotting. Figure 3 shows the IgG
and IgM responses with the outbreak strain for 25
randomly chosen UAT-negative cases. Antibody binding
to the LPS region below 25 kDa dominated in addition
to individual antibody reactions in the 25 to 80 kDaJune 2005
27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12
Legionnaires’ disease, UAT/culture verified (n=53)
Legionnaires’ disease, serologically verified (n=46)
CAP, non-LD (n=94)
CAP of uncertain Legionella status (n=32)
umonia (CAP) by date of admission to the hospital.
+  - - - - - - + (+)(+)+ - (+)(+) - + (+) +  - - - - - +   -
IgG
a
Patient no.
1          5              10            15           20              25
+  - +   - +  - (+)(+) - - (+) +  - - +  - (+) + + (+)(+)(+) -(+)(+)
IgM
b1           5              10            15            20            25 
Figure 3 IgG and IgM binding to the outbreak strain with sera
from UAT negative LD cases. The immunoblots show IgG and IgM
antibody binding, respectively, with sera from 25 UAT-negative cases
to whole cells of the L. pneumophila serogroup 1 outbreak strain.
Individual cases are identified by numbers above the nitrocellulose
strips, and the upper and lower arrows to the right show the positions
of proteins of molecular masses of approx. 80 kDa and 25 kDa,
respectively. Strip a: binding of a monoclonal antibody to serogroup 1
L. pneumophila (Lp 1 from the Dresden panel [26]); strip b: IgM
antibody reactions of serum from case no. 25 from another experiment
with proteinase K treated cells, showing the ladder-like LPS antibody
responses. IgG and IgM binding intensities of each serum to LPS are
rated below the strips as + (strong), (+) (weak), and – none. Each 12%
acrylamide gel was loaded with whole cells from the outbreak strain,
corresponding to 2 μg protein/strip, and the strips were incubated
with 1:200 serum dilutions. UAT: urine antigen test.
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intensities to the LPS region below 25 kDa corresponded
with intensities of a smear in the higher molecular weight
range. Among all 45 UAT-negative cases, 30 (67%) had
IgG and/or IgM antibodies that showed strong (16 cases)
or weak binding (14 cases) to LPS on the blots. A similar
proportion of the UAT-positive cases/(30/44; 68%) also
showed corresponding LPS bands (19 and 11 cases with
strong and weak bands, respectively), whereas no such
reactions were observed with sera from the 39 confirmednon-LD patients (data not shown). LPS band intensities
generally corresponded to the IgG or IgM antibody levels
in ELISA. Proteinase K treatment of the outbreak strain
gave similar LPS responses as the untreated cells, but the
distinct high molecular weight bands were absent and
the ladder-like LPS pattern below 25 kDa became more
distinct after proteolysis (Figure 3; strip b). In comparison
with these LPS responses, 15 (33%) and 26 (59%) of the
sera from the UAT-negative and UAT-positive cases, re-
spectively, demonstrated strong or weak LPS bands with
a proteolytically treated serogroup 1 France/Allentown
isolate (data not shown). Thus, more UAT-positive cases
seemed to have cross-reactive antibodies to this strain
than the UAT-negative cases.Discussion
This Legionella outbreak demonstrated the challenges of
the microbiological diagnosis of LD: 1) the acute phase
tests (culture, PCR, and UAT) underestimated the num-
ber of cases; 2) the traditional serological criterion of a
≥4-fold titre increase yielded poor sensitivity in this
outbreak population; and 3) even when all diagnostic
tests were employed, there was still an unexplained
excess of hospitalized CAP patients in whom Legionella
infection could not be verified or excluded indicating
shortcomings of the microbiological tools. Previously,
the acute phase tests diagnosed 56 LD outbreak cases
[16]. Our study identified an additional 47 cases with the
serological assays, thus the outbreak comprised a total of
103 LD cases, of whom 87 were confirmed and 16 were
probable cases. Another group of 32 patients with CAP
of high mortality may also belong to the outbreak.
UAT has emerged as the most common test for
laboratory diagnosis of LD [2] because of its simplicity
and high specificity. Although it was useful during the
acute phase, UAT was positive in only 52 of the 99 cases
(53%) who were tested (Table 2). This number corre-
sponded to those from two other outbreaks [28,29] and
a recent methodological study [30]. However, a meta-
analysis [14] reported a sensitivity of 74%, and in infec-
tions caused by Lp 1 strains with the virulence-associated
epitope, recognized by the 3/1 monoclonal antibody [26]
including the outbreak strain [15], the sensitivity was more
than 90% [13]. As UAT has lower sensitivity in mild LD
[12], the sensitivity discrepancy is probably due to the
broader clinical spectrum including less severe CAP in the
outbreak population. Besides UAT, only four more cases
were identified by culture of sputum and lung tissue and
none by PCR, but fewer samples were analysed by these
two assays (Table 2).
Evaluation of the serological assays (Table 1) demon-
strated lower sensitivity than Yzerman et al. [18] reported
with LD patients from the large Dutch outbreak with the
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vs. 61%) and ELISA seroconversion (30% vs. 64%). How-
ever, the results were more similar for the high standing
titre definition (73% vs. 86% in IFA and 68% vs. 75% in
ELISA). Early sampling may lead to higher sensitivity; in
our study, the mean time from disease onset to sampling
of the acute-phase sera was 11 days (range 5 – 15) com-
pared with 8 days (range 0 – 15) in the Dutch study [18].
This suggested that seroconversion may already have
occurred, especially for IgM antibodies [31]. The use of
paired sera from LD cases in the evaluation study
(Table 1) further indicated the presence of exclusion bias
as the most severely ill LD cases died before convalescent
sera could be sampled. Thus, the low mortality among
the LD cases in our evaluation study (0% vs. 9% in the
Dutch study), indicating differences in illness severity,
and the different Lp 1 strains in the two outbreaks [18]
may present alternative explanations for the divergent
results. Our study did not demonstrate any association
between the sensitivity of the serological tests and pneu-
monia severity, but the statistical power was low.
The alternative ELISA evaluation, based on the ratios
in paired samples of IgG and IgM ≥ 1.5, respectively,
showed the highest combined sensitivity and specificity
of the three evaluated case-definitions (Table 1). The
higher sensitivity was obtained because several cases
with high ratios were negative according to the manu-
facturer’s cut-off. A similar method has been validated
in ELISA for infections caused by Mycoplasma pneu-
monia and Chlamydophila pneumonia [32,33], but to
our knowledge, this method, which detected six add-
itional LD cases (Table 2), has not previously been
applied for Legionella testing. As about 20-30% of LD
patients do not develop significantly increased antibody
levels even after prolonged observation [34], the ad-
vantage of this method is to ignore an absolute cut-off
level which must be set high in order to produce a
low level of false positives. The challenge remains to
find a reasonable cut-off to avoid clinically irrelevant
changes in the low antibody range, and the specificity
will probably suffer in a non-outbreak study.
Selection of non-cases for evaluation of the specificity
was not optimal. Ideally, this group should consist of
non-LD CAP patients only, but misclassification was
difficult to avoid because of the epidemiological situation
and the low negative predictive value of a negative UAT.
We therefore included healthy controls to increase the
power of the specificity analysis. Although this group
was also exposed to the Legionella outbreak, as demon-
strated by the slightly higher antibody levels among
healthy blood donors in the outbreak county compared
with donors in a non-exposed county [23], it differed
from the CAP population in both age and past medical
history which might have affected the results. There wasno seroconversion in the healthy control group, and
the antibody levels (median IgG 9 U/ml, range 1 – 111
U/ml, and median IgM 14 U/ml, range 2 – 82 U/ml)
were comparable to those demonstrated one year after
the outbreak in healthy blood donors from the same
county [23].
As the polyvalent antigens in the ELISA and IFA may
affect the case definitions, immunoblotting with the Lp
1 outbreak strain was performed to investigate if the
antibody responses were directed to the serogroup-
specific LPS antigen of this strain. These experiments
showed that two-thirds of both the UAT-positive and
the UAT-negative LD cases had IgG and/or IgM anti-
bodies that reacted with the LPS. About the same pro-
portion of the UAT-positive cases, but only 30% of the
UAT-negative cases showed cross-reactive antibodies
with LPS of a subgroup France/Allentown Lp 1 strain
that also carry the virulence-associated monoclonal 3/1
epitope [26]. It is less likely that this cross-reaction is
caused by infection of France/Allentown strains as these
are rarely seen in Norway after 2001 [15]. Some cross-
reactions may probably occur as various subgroups of
Lp 1 strains show the same ladder-like profiles in silver-
stained gels [35]. A rabbit serum to one Lp1 subgroup
was found to cross-react with the other subgroups on
immunoblots, but a corresponding reaction was only
observed with a few of the 14 serogroups of L. pneumo-
phila [35,36]. In Norway, the incidence of LD is low, and
only a small number of seroresponders (2.3%) among
healthy blood donors was observed in the outbreak
county [23]. Together with the same antibody levels
(Table 3) in the UAT positive and negative cases, the
same LPS-specific antibody responses, the same time
period, and home addresses, our findings suggested that
the UAT-negative LD cases were most likely infected
with the outbreak strain and not with other L. pneumo-
phila strains.
This LD outbreak probably included more than the
103 verified cases. The average number of patients
referred to our hospital with CAP during the same five-
week period in the preceding four years was 80 (range
72–86). Comparison of this number with the 225 CAP
patients admitted during the outbreak in 2005 (Figure 1),
indicated an excess of 145 patients and possible LD
cases. This observation may be supported by another
outbreak study which suggested that UAT and culture
detected less than 40% of the LD patients, when the
unexplained excess of CAP patients with possible LD
was taken into consideration [29]. Based on a similar
assumption for this outbreak (56 cases originally de-
tected = 40% of the outbreak), we might expect to find
about 140 patients with LD. A major limitation of these
calculations was the uncertainty of increased referral
because of the outbreak alert. However, no more than 15
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Figure 2. Compared with the previous four years, the
proportion of outpatient treatment was approximately
the same indicating comparable referral and admission
strategies. Furthermore, in 32 hospitalized CAP patients
with high mortality, Legionella infection could not be
ruled out based on epidemiological or laboratory criteria.
A considerable proportion of these was admitted during
the main bulk of referrals immediately before the out-
break was recognized (Figure 2). This finding suggested
that the incidence is underestimated even in prospective
studies. Underdiagnosis of non-severe LD might not
seem important as the mortality is low. However, re-
covery from LD is poorly studied, but might include
reduced pulmonary function [37,38], fatigue, and even
posttraumatic stress disorder [39].Conclusions
Our study demonstrated that serological testing is a
valuable tool to determine the total number of patients
during an LD outbreak investigation. The serological
assays detected 47 more cases than the 56 cases previ-
ously diagnosed by culture, PCR, and/or UAT. To our
knowledge, the Legionella outbreak in 2005 in Norway is
the largest outbreak reported until now in the Nordic
countries.
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